Organization · Venture Capital
Biovision Ventures
Biovision Ventures is a venture capital firm investing in early-stage therapeutics and digital health opportunities primarily in the US and Europe. The firm focuses on innovative life sciences companies that aim to translate scientific advancements into transformative therapies.
Overview
What Biovision Ventures does
What Biovision Ventures is
Biovision Ventures is a venture capital firm investing in early-stage therapeutics and digital health opportunities primarily in the US and Europe. The firm focuses on innovative life sciences companies that aim to translate scientific advancements into transformative therapies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Structured capabilities
- Funder
- Last reviewed
- March 27, 2026
Official channels
Find Biovision Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
Biovision Ventures as a funder
Investment thesis
Biovision Ventures focuses on early-stage life sciences and healthcare companies, aiming to translate scientific advancements into transformative therapies.
Focus narrative
The firm invests primarily in therapeutics and Bio-IT, focusing on platform-based therapeutic approaches and medical software solutions for clinical use. Biovision Ventures is agnostic regarding specific diseases and modalities, allowing for a broad investment scope within the life sciences sector.
Value beyond capital
Biovision Ventures adds value to its portfolio companies by actively participating in their growth, often taking board seats and leveraging its expertise to guide them towards early value inflection points.
Terms and economics
- Typical check
- $1,650,000–$3,300,000
Focus and fit
- Stages
- Pre-seed · Seed · Series A · Series B
- Regions
- EuropeUnited States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded notable exits
- Retrosense Therapeutics and Bonti
Portfolio context
Notable portfolio companies include Tune Therapeutics, Retrosense Therapeutics (acquired by Allergan for $555 million), Bonti (acquired by Allergan for $285 million), and Hawthorne Health.
Common questions
What to know about Biovision Ventures
Upseed classifies Biovision Ventures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 27, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.